Dr. Julie Master, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 166 Morris Ave, Long Branch, NJ 07740 Phone: 732-263-5024 Fax: 732-263-5029 |
Dr. Bernard Pellman Shagan, M.D. Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 300 2nd Ave, Department Of Medicine, Long Branch, NJ 07740 Phone: 732-222-5200 Fax: 732-741-3082 |
Charles Louis Spellman, DO Internal Medicine Medicare: Medicare Enrolled Practice Location: 300 2nd Ave, Long Branch, NJ 07740 Phone: 732-923-6696 |
August Wreiole, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 422 Morris Ave, Long Branch, NJ 07740 Phone: 732-222-0200 |
Dr. Marek Mrzyglocki, M.D. Internal Medicine - Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 215 Brighton Ave, Long Branch, NJ 07740 Phone: 732-222-1543 Fax: 732-774-9148 |
Masako Mizusawa, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 300 2nd Ave, Long Branch, NJ 07740 Phone: 732-222-5200 |
Mrs. Yuliya Nudelman, M.D. Internal Medicine - Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 300 2nd Ave, Long Branch, NJ 07740 Phone: 732-222-5200 |
Jyothi Asthana, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 300 2nd Ave, Long Branch, NJ 07740 Phone: 732-923-6540 Fax: 732-923-6536 |
News Archive
The NFL will fund a $2.6 million international study on the role of active rehabilitation strategies in concussion management, led by the University of North Carolina at Chapel Hill and the Medical College of Wisconsin.
The National Association For Continence has designated Beth Israel Deaconess Medical Center as a Center of Excellence: Continence Care. Anurag K. Das, MD; Roger Lefevre, MD; Janet Li, MD; and Deborah A. Nagle, MD are the principle physicians for this COE.
AstraZeneca (NYSE: AZN) today announced that data from a Phase III study of postmenopausal women with hormone receptor-positive advanced breast cancer presented at the San Antonio Breast Cancer Symposium (Abstract 25) showed treatment with fulvestrant (FASLODEX) 500 mg reduced the risk of disease progression (assessed as time to progression (TTP)) by 20%
Catasys, Inc., provider of proprietary health management services to health insurers and employers, today reported full year 2014 financial results for the period ended December 31, 2014.
› Verified 4 days ago